ArticlePloS one2013
Mifepristone promotes adiponectin production and improves insulin sensitivity in a mouse model of diet-induced-obesity.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- A multi-omic atlas in the African turquoise killifish reveals increased glucocorticoid signaling as a hallmark of brain aging.bioRxiv : the preprint server for biology · 2026Article
- Liver impairment and medical management of Cushing syndrome and MACS.Frontiers in endocrinology · 2025Review
- Effects of mifepristone on adipocyte differentiation in mouse 3T3-L1 cells.Cellular & molecular biology letters · 2024Article
- Article
- Article
- The Hepatoprotective and Hepatotoxic Roles of Sex and Sex-Related Hormones.Frontiers in immunology · 2022Review
- Mifepristone Increases Life Span in FemaleFrontiers in aging · 2022Article
- Mifepristone Increases Life Span of Virgin FemaleFrontiers in genetics · 2021Article
- Mitigation of metabolic dyshomeostasis by glucocorticoid-receptor antagonism: Insights from animal and human studies.EXCLI journal · 2020Article
- Mifepristone for Treatment of Metabolic Syndrome: Beyond Cushing's Syndrome.Frontiers in pharmacology · 2020Article
- Fast Adipogenesis Tracking System (FATS)-a robust, high-throughput, automation-ready adipogenesis quantification technique.Stem cell research & therapy · 2019Article
- Lack of direct effect of adiponectin on vascular smooth muscle cell BKPhysiological reports · 2017Article
- Glucocorticoids Retain Bipotent Fibroblast Progenitors during Alveolar Septation in Mice.American journal of respiratory cell and molecular biology · 2017Article
- Postnatal treatment with metyrapone attenuates the effects of diet-induced obesity in female rats exposed to early-life stress.American journal of physiology. Endocrinology and metabolism · 2017Article
- A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.International journal of obesity (2005) · 2016Article
- Dietary fat and corticosterone levels are contributing factors to meal anticipation.American journal of physiology. Regulatory, integrative and comparative physiology · 2016Article
- Biochemical and Radiological Changes in Liver Steatosis Following Mifepristone Treatment in Patients With Hypercortisolism.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The steroid receptor antagonist mifepristone is used as an anti-cancer agent, eliciting both cytostatic and cytotoxic effects on malignant cells. However, the metabolic effects of long-term treatment with mifepristone have remained unclear. The effects of mifepristone on insulin sensitivity and adiponectin secretion were evaluated both in in vivo and in vitro. First, we explored the effects of mifepristone, on metabolic functions in obese mice receiving a high-fat diet. When these mice were fed mifepristone, they exhibited a marked improvement in insulin sensitivity, attenuated hepatic injury, and decreased adipocyte size, compared with mice that received only the high-fat diet. Intriguingly, mifepristone-treated mice showed significantly elevated plasma adiponectin levels. Second, we tested the effects of mifepristone on differentiated 3T3-L1 adipocytes in vitro. When differentiated adipocytes were treated with mifepristone for 48 h, adiponectin was upregulated at both mRNA and protein levels. Collectively, these results reveal novel actions of mifepristone on metabolic functions, in vivo and in vitro, in which the drug exerts antidiabetic effects associated with an upregulation in adiponectin-secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.